Objectives. We endeavored to retrospectively assess the prognostic merit of pretreatment systemic immune response index (SIRI) in glioblastoma multiforme (GBM) patients who underwent postoperative partial brain radiotherapy (RT) and concurrent plus adjuvant temozolomide (TMZ), namely, the Stupp protocol. Methods. The records of 181 newly diagnosed GBM patients who received the postoperative Stupp protocol were retrospectively analyzed. The SIRI value for each eligible patient was calculated by utilizing the platelet, neutrophil, and lymphocyte measures obtained on the first day of treatment: . The ideal cutoff values for SIRI connected with the progression-free- (PFS) and overall survival (OS) results were methodically searched through using the receiver operating characteristic (ROC) curve analysis. Primary and secondary end-points constituted the potential OS and PFS distinctions among the SIRI groups, respectively. Results. The ROC curve analysis labeled the ideal SIRI cutoffs at 1.74 (Area under the curve (AUC): 74.9%; sensitivity: 74.2%; specificity: 71.4%) and 1.78 (AUC: 73.6%; sensitivity: 73.1%; specificity: 70.8%) for PFS and OS status, individually. The SIRI cutoff of 1.78 of the OS status was chosen as the common cutoff for the stratification of the study population (Group 1: () and ()) and further comparative PFS and OS analyses. Comparisons between the two SIRI cohorts manifested that the cohort had altogether significantly superior median PFS (16.2 versus 6.6 months; ) and OS (22.9 versus 12.2 months; ) than its counterparts. The results of multivariate Cox regression analyses ratified the independent and significant alliance between a low SIRI and longer PFS () and OS () durations, respectively. Conclusions. Present results firmly counseled the pretreatment SIRI as a novel, sound, and independent predictor of survival outcomes in newly diagnosed GBM patients intended to undergo postoperative Stupp protocol.

中文翻译：

---

全身炎症反应指数可预测接受标准 Stupp 方案治疗的多形性胶质母细胞瘤患者的生存结果

目标。我们努力回顾性评估接受术后部分脑放疗（RT）和同时加辅助替莫唑胺（TMZ）的多形性胶质母细胞瘤（GBM）患者治疗前全身免疫反应指数（SIRI）的预后价值，即Stupp方案。方法。回顾性分析接受术后Stupp方案的181例新诊断GBM患者的记录。通过利用治疗第一天获得的血小板、中性粒细胞和淋巴细胞测量值计算每个符合条件的患者的 SIRI 值：. 通过使用受试者工作特征 (ROC) 曲线分析有条不紊地搜索与无进展 (PFS) 和总生存期 (OS) 结果相关的 SIRI 的理想截止值。主要和次要终点分别构成了 SIRI 组之间潜在的 OS 和 PFS 差异。结果。ROC 曲线分析将理想的 SIRI 截断标记为 1.74（曲线下面积 (AUC)：74.9%；敏感性：74.2%；特异性：71.4%）和 1.78（AUC：73.6%；敏感性：73.1%；特异性：70.8% ) 分别用于 PFS 和 OS 状态。OS 状态的 1.78 的 SIRI 截止值被选为研究人群（第 1 组：()和())以及进一步的比较 PFS 和 OS 分析。两个 SIRI 队列之间的比较表明，队列的中位 PFS 完全显着优越（16.2 个月对 6.6 个月；)和 OS（22.9 个月对 12.2 个月；)比它的同行。多变量 Cox 回归分析的结果证实了低 SIRI 和较长 PFS 之间的独立且显着的关联（)和操作系统 ()持续时间，分别。结论。目前的结果坚定地建议治疗前 SIRI 作为新诊断的打算接受术后 Stupp 方案的 GBM 患者的生存结果的一种新颖、可靠和独立的预测指标。